For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- Blopress, Nu-lotan Up Remarkably, But Mevalotin, Lipovas Down: Top 100 Products
July 2, 2001
- 48 New Active Ingredients Approved in FY2000
July 2, 2001
- Otsuka to Acquire Meretek of the US
July 2, 2001
- Takeda's Ixense for ED Launched in France, Germany
July 2, 2001
- MEDICAL DEVICE NEWS IN BRIEF
July 2, 2001
- Kyowa Hakko to Sell Mohan to Merck Hoei
July 2, 2001
- WORLD NEWS IN BRIEF
July 2, 2001
- Dainippon Launches Gasmotin in China
July 2, 2001
- OTC NEWS IN BRIEF
July 2, 2001
- EAD Director Urges Generic Houses to Expand Their Sales Route
July 2, 2001
- Takeda to Invest \110 Billion in R&D for FY2001
July 2, 2001
- 14 New Ingredients Officially Clear Regulatory Approval
July 2, 2001
- Long-term Continuous Use of Rocornal Reduces Cardiac Events
July 2, 2001
- Adalat Inhibits Carotid Artery Thickening: INSIGHT Side-arm Study
July 2, 2001
- Kirin, Corixa to Jointly Develop Antibody Drugs by Using TC Mouse
July 2, 2001
- BUSINESS NEWS IN BRIEF -2-
July 2, 2001
- 2001 Novartis Foundation Grant for Gerontological Research Goes to 5 People
July 2, 2001
- BUSINESS NEWS IN BRIEF -1-
July 2, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
July 2, 2001
- China, Taiwan Added to Servier's Territory for Kissei's Mitiglinide
July 2, 2001
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…